Niagen Bioscience (NAGE) EBITDA Margin (2010 - 2026)
Niagen Bioscience (NAGE) posted quarterly EBITDA Margin of 5.01% for Q1 2026, down 1065.0% year-over-year from 0.52% in Q1 2025, and down 58.53% quarter-over-quarter from 12.07% in Q4 2025.
Niagen Bioscience (NAGE) EBITDA Margin (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported EBITDA Margin for 17 consecutive years, with 5.01% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 1065.0% year-over-year to 5.01%; the TTM figure through Mar 2026 stood at 10.03% (down 223.0% YoY), while the FY2025 annual figure was 12.58%, up 482.0% from the prior year.
- EBITDA Margin eased to 5.01% in Q1 2026 per NAGE's latest filing, from 12.07% in the prior quarter.
- Across five years, EBITDA Margin topped out at 24.42% in Q4 2024 and bottomed at 44.8% in Q1 2022.
- Historically, EBITDA Margin has averaged 3.11% across 5 years, with a median of 1.13% in 2024.
- Annual changes were most pronounced in 2023 — EBITDA Margin soared 3607 bps — and 2025, when it slumped 1234 bps.
- Niagen Bioscience's EBITDA Margin stood at 6.88% in 2022, then jumped by 88 bps to 0.79% in 2023, then surged by 3180 bps to 24.42% in 2024, then slumped by 51 bps to 12.07% in 2025, then sank by 59 bps to 5.01% in 2026.
- Business Quant data shows NAGE's EBITDA Margin at 5.01% in Q1 2026, 12.07% in Q4 2025, and 12.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 2.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.35% |
| Mar 31, 2026 | 5.01% |
| Dec 31, 2025 | 12.07% |
| Sep 30, 2025 | 12.46% |
| Jun 30, 2025 | 10.24% |
| Mar 31, 2025 | 15.66% |
| Dec 31, 2024 | 24.42% |
| Sep 30, 2024 | 6.26% |
| Jun 30, 2024 | -1.13% |
| Mar 31, 2024 | -3.30% |
| Dec 31, 2023 | -0.79% |
| Sep 30, 2023 | -5.88% |
| Jun 30, 2023 | -11.40% |
| Mar 31, 2023 | -8.72% |
| Dec 31, 2022 | -6.88% |
| Sep 30, 2022 | -17.96% |
| Jun 30, 2022 | -38.17% |
| Mar 31, 2022 | -44.80% |
| Dec 31, 2021 | -29.93% |
| Sep 30, 2021 | -51.08% |